TENAX THERAPEUTICS, INC. — Form 10-Q
Filed July 31, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Tenax Therapeutics (via successor Phyxius Pharma) entered into a Supply Agreement with Orion Corporation dated June 29, 2026, governing manufacture and supply of an orally administered levosimendan product (1mg capsules) and placebo products. Orion will be the primary supplier; Tenax has contingent rights to source from third parties upon supply failure or termination. Key commercial terms redacted [***]. Agreement includes industrialization cost-sharing, technical transfer rights, quality standards, and a 5-year initial term with 3-year renewal options. Most specific pricing, forecast quantities, and payment terms are confidentiality-marked.
Why this rating
Supply agreement is routine operational matter for ~$24M biotech. Levosimendan is early-stage; redacted terms prevent full assessment. No equity issuance, financing, or go-concern risk evident.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.